GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (LTS:0A50) » Definitions » Valuation Rank

Co-Diagnostics (LTS:0A50) Valuation Rank


View and export this data going back to 2020. Start your Free Trial

What is Co-Diagnostics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Co-Diagnostics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Co-Diagnostics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Co-Diagnostics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (LTS:0A50) » Definitions » Valuation Rank
Comparable Companies
PAVM INBS BTCY BMRA SSKN NURO DHAI AIMD TNON AEMD ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
CODX:USA C97:Germany C97:Germany
Address
2401 South Foothill Drive, Salt Lake City, UT, USA, 84109
Website
https://www.codiagnostics.com
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.